0001504167-17-000006.txt : 20170221 0001504167-17-000006.hdr.sgml : 20170221 20170221160609 ACCESSION NUMBER: 0001504167-17-000006 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170214 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20170221 DATE AS OF CHANGE: 20170221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioPharmX Corp CENTRAL INDEX KEY: 0001504167 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 593843182 STATE OF INCORPORATION: DE FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37411 FILM NUMBER: 17625078 BUSINESS ADDRESS: STREET 1: 1505 ADAMS DRIVE, SUITE D CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-889-5020 MAIL ADDRESS: STREET 1: 1505 ADAMS DRIVE, SUITE D CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: THOMPSON DESIGNS INC DATE OF NAME CHANGE: 20101022 8-K 1 bpmx-20170214x8k.htm 8-K BPMX 8K misc filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8‑K

 

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report: February 14, 2017

(Date of earliest event reported)

 

BIOPHARMX CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

 

001-37411

 

59-3843182

(Commission File Number)

 

(IRS Employer Identification No.)

 

1505 Adams Drive, Suite D

Menlo Park, California

 

 

94025

(Address of Principal Executive Offices)

 

(Zip Code)

 

 

(650) 889-5020

(Registrant’s Telephone Number, Including Area Code)

 

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

⃞ Soliciting material pursuant to Rule 14a‑12 under the Exchange Act (17 CFR 240.14a‑12)

⃞ Pre‑commencement communications pursuant to Rule 14d‑2(b) under the Exchange Act (17 CFR 240.14d‑2(b))

⃞ Pre‑commencement communications pursuant to Rule 13e‑4(c) under the Exchange Act (17 CFR 240.13e‑4(c))

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(e)

 

On February 14, 2017, the Compensation Committee (the “Committee”) of the Board of Directors of BioPharmX Corporation (the “Company”) approved cash bonuses of (i) $60,000 to Anja Krammer, the Company’s President, (ii) $10,000 to Greg Kitchener, the Company’s Executive Vice President and Chief Financial Officer and (iii) $25,000 to Kin F. Chan, the Company’s Executive Vice President of Research and Technology.  These bonuses were based on their achievements in fiscal year 2017 and are expect to be paid in the first quarter of fiscal year 2018. The Committee also approved increases in the annual base salary to the foregoing officers such that their annual base salaries, effective as of February 1, 2017, are as follows: (x) $310,000 for Anja Krammer, (y) $237,000 for Greg Kitchener and (z) $270,000 for Kin F. Chan.

 

 

 

 

 

 

 

 

 

3

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

                 

BIOPHARMX CORPORATION

                   

 

Date: February 21, 2017By:/s/ Greg Kitchener

             Name:  Greg Kitchener

Title:  Chief Financial Officer